Clinical Trials
22 trialsNCT06161922 2023-12-08
Real World Patient-Reported Outcomes in Chinese Her2+ EBC Patients Receiving (Neo) Adjuvant Anti-Her2 Based Therapy
Fudan University
Unknown
NCT05985187 2023-08-14
Clinical Study to Evaluate the Efficacy and Safety of TQB2440 Injection/Perjeta® Combined With Trastuzumab and Docetaxel in the Treatment of Patients With Early or Locally Advanced Breast Cancer.
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Phase 3 Unknown
NCT05945368 2023-07-14
A Trial of Eribulin in Combination With HP Neoadjuvant Therapy in Patients With for HER2-Positive BC
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Phase 2 Unknown
NCT05720026 2023-02-09
Study to Evaluate the Efficacy and Safety of SYSA1901 vs. Perjeta® of HER2-Positive Breast Cancer
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.
Phase 3 Unknown
NCT04288141 2022-11-14
HERdi PREDICT
King's College London
Unknown
NCT05561686 2022-09-30
Real-world Study of Pyrotinib in Neoadjuvant Therapy for HER2-positive Breast Cancer
Hunan Cancer Hospital
Unknown
NCT05429294 2022-06-23
Novel Double Target Therapy Combined With Chemotherapy in First-line Treatment of HER2+ Breast Cancer, MA-BC-II-038
First Affiliated Hospital Xi'an Jiaotong University
Phase 2 Unknown
NCT05334810 2022-04-19
DP303c in Patients With HER2-positive Unresectable Locally Advanced, Relapsed, or Metastaticbreast Cancer
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.
Phase 2 Unknown
NCT05189067 2022-01-12
Efficacy and Safety of Adjuvant Docetaxel and Trastuzumab in Stage I HER2-positive Breast Cancer
Second Affiliated Hospital, School of Medicine, Zhejiang University
Phase 2/3 Unknown
NCT05154396 2021-12-13
Neratinib Dose Escalation Regimen for HER2 Positive Early Breast Cancer
ChineseAMS
Phase 2 Unknown
NCT03238495 2021-12-07
HERMET
University of Kansas Medical Center
Phase 2 Unknown
NCT03655353 2021-09-29
Affibody-3
Uppsala University Hospital
Phase NA Unknown
NCT04170595 2021-03-03
Clinical Study of Recombinant Anti-HER2 Humanized Monoclonal Antibody for Injection
Genor Biopharma Co., Ltd.
Phase 1/2 Unknown
NCT03933319 2020-07-08
Phase Ⅱ Study of Pegylated Liposomal Doxorubicin（PLD）Plus Trastuzumab in HER-2 Positive Metastatic Breast Cancer
ChineseAMS
Phase 2 Unknown
NCT04158505 2020-04-24
Real World Study of Pyrotinib in Human Epidermal Growth Factor Receptor-2 (HER2) Positive Breast Cancer
ChineseAMS
Unknown
NCT04276337 2020-02-19
Genetic Characteristics of HER2 Positive Breast Cancer With Neoadjuvant TCHP Chemotherapy
Samsung Medical Center
Unknown
NCT04034823 2019-07-26
KN035 in Combination With Trastuzumab and Docetaxel in HER2-positive Breast Cancer
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Phase 2 Unknown
NCT04011085 2019-07-08
Tw HER2 Positive Breast Cancer Productivity & Utility Study
Taiwan Epidemiology Association
Unknown
NCT03919253 2019-04-18
Pyrotinib in Combination With Nab-paclitaxel in Patients With HER2-positive Advanced Breast Cancer: an Exploratory Study
Hebei Medical University Fourth Hospital
Phase 2 Unknown
NCT03881878 2019-03-21
TAHP for Patients With HER2-positive Early Breast Cancer and Subsequent AHP Adjuvant tHerapy After Surgery
Samsung Medical Center
Phase 1/2 Unknown
NCT03847818 2019-03-01
Neoadjuvant Study of Pyrotinib and Trastuzumab Plus Chemotherapy in Patients With HER2 Positive Breast Cancer
Shandong University
Phase NA Unknown
NCT03684863 2018-09-26
Capecitabine in HER-2 Positive Breast Cancer With Pathologic Residual Tumors After Preoperative Chemotherapy
Shandong Cancer Hospital and Institute
Phase 2 Unknown